Pharma: Clinic Roundup
Tuesday, October 15, 2013
• Lurasidone, an atypical antipsychotic developed by Dainippon Sumitomo Pharma Co. Ltd., of Osaka, Japan, and marketed by its subsidiary Sunovion Pharmaceuticals Inc., of Marlborough, Mass., was the subject of five poster presentations at the 26th European College of Neuropsychopharmacology Congress in Barcelona, Spain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.